Inhibitors of the EGF-receptor tyrosine kinase and methods...

Details Inhibitors of the EGF-receptor tyrosine kinase and methods... Inhibitors of the EGF-receptor tyrosine kinase and methods...

2005-03-08

2005-03-08

Solola, Taofiq (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C558S305000

Reexamination Certificate

active

06864286

ABSTRACT:
Novel compounds and pharmaceutical compositions useful as EGFR tyrosine kinase inhibitors. Methods of the invention include administration of the EGFR TK inhibitors to treat diseases characterized by enhanced expression of EGF, including cancers, particularly breast cancer. Additionally, a homology model representing the structure of EGFR kinase domain is provided, which model is useful for the rationally design and screening of compounds predicted to bind favorably to EGFR and to inhibit EGFR TK.

REFERENCES:
patent: 4061767 (1977-12-01), Ertel et al.
patent: 4346097 (1982-08-01), Schweiss et al.
patent: 4559157 (1985-12-01), Smith et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4820508 (1989-04-01), Wortzman
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 5240960 (1993-08-01), Hambleton et al.
patent: 5532259 (1996-07-01), Bartlett et al.
patent: 5747664 (1998-05-01), Schleyerbach et al.
patent: 5780592 (1998-07-01), Mullner et al.
patent: 5977151 (1999-11-01), Mullner et al.
patent: 6218388 (2001-04-01), Boschelli et al.
patent: 196 10 955 (1997-09-01), None
patent: 1 571 990 (1980-07-01), None
patent: WO 9424095 (1994-10-01), None
Abrams, M.D., J. S. et al., “New Chemotherapeutic Agents for Breast Cancer”,Cancer, vol. 74, No. 3, pp. 1164-1176 (Aug. 1, 1994).
Bacon, D. J. et al., “A Fast Algorithm for Rendering Space-Filling Molecule Pictures”,J. Molec. Graphics, vol. 6, No. 4, pp. 219-220 (Dec. 1988).
Bertolini, G., et al., “A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug”,J. Med. Chem, vol. 40, No. 13, pp. 2011-2016 (Jun. 20, 1997).
Bohm, H. J., “LUDI: Rule-Based Automatic Design of New Substituents for Enzyme Inhibitor Leads”,J. Comput. Aided Mol. Des., vol. 6, No. 6, pp. 593-606 (Dec. 1992).
Bohm, H. J., “The Development of a Simple Empirical Scoring Function to Estimate the Binding Constant for a Protein-Ligand Complex of Known Three-Dimensional Structure”,J. Comput. Aided Mol. Des., vol. 8, No. 3, pp. 243-256 (Jun. 1994).
Chrysogelos, S.A. et al., “EGF Receptor Expression, Regulation, and Function in Breast Cancer”,Breast Cancer Res.Treat., vol. 29, pp. 29-40 (1994).
Connolly, M. L., “Solvent-Accessible Surfaces of Proteins and Nucleic Acids”,Science, vol. 221, pp. 709-713 (Aug. 19, 1983).
Courville, P. et al., “Pseudoepitheliomatous Hyperplasia in Cutaneous Tcell Lymphoma. A Clinical, Histopathological and Immunohistochemical Study with Particular Interest in Epithelial Growth Factor Expression”,British Journal of Dermatology, vol. 140, No. 3, pp. 421-426 (Mar. 1999).
De Luca, A. et al., “Detection of Circulating Tumor Cells in Carcinoma Patients by a Novel Epidermal Growth Factor Receptor Reverse Transcription-PCR Assay”,Clin. CancerRes., vol. 6, No. 4, pp. 1439-1444 (Apr. 2000) (Abstract Only).
Fox, S.B, et al., “The Epidermal Growth Factor Receptor as a Prognostic Marker: Results of 370 Patients and Review of 3009 Patients”,Breast Cancer Res.Treat., vol. 29, pp. 41-49 (1994).
Fry, D. W. et al., “Inhibitors of Protein Tyrosine Kinases”,Curr. Opin. Biotechnol, vol. 6, No. 1, pp. 662-667 (Feb. 1995).
George-Nascimento et al., “Characterization of Recombinant Human Epidermal Growth Factor Produced in Yeast”,Biochemistry, vol. 27, pp. 797-802 (1988).
Ghosh, S. et al., “α-Cyano-β-hydroxy-β-methyl-N-[4-(trifluoromethoxy)phenyl] Propenamide: An Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase with Potent Cytotoxic Activity against Breast Cancer Cells”,Clinical Cancer Research, vol. 4, pp. 2657-2668 (Nov. 1998).
Goodman, P. A. et al., “Role of Tyrosine Kinases in Induction of c-jun Proto-oncogene in Irradiated B-lineage Lymphoid Cells”, vol. 273, No. 28, pp. 17742-17748 (Jul. 10, 1998).
Gusterson, B. et al., “Cellular Localisation of Human Epidermal Growth Factor Receptor”,Cell Biology International Reports, vol. 8, No. 8, pp. 649-658 (Aug. 1984).
Hermanson, et al.,Bioconjugate Techniques, Academic Press, 1996.
Hermanson, et al.,Immobilized Affinity Ligand Techniques, Academic Press, 1992.
Hubbard, S. R., “Crystal Structure of the Activated Insulin Receptor Tyrosine Kinase in Complex with Peptide Substrate and ATP Analog”,The E.M.B.O. Journal, vol. 16, No. 18, pp. 5572-5581 (1997).
Khazale, K. et al., “EGF Receptor in Neoplasia and Metastatis”,Cancer&Metasis Reviews, vol. 12, pp. 255-274 (1993).
Kraulis, P.J., “MOLSCRIPT: A Program to Produce Both Detailed and Schematic Plots of Protein Structures”,J. Appl. Cryst, vol. 24, pp. 946-950 (Oct. 1, 1991).
Kuntz, I. D. et al., “A Geometric Approach to Macromolecule-Ligand Interactions”,J. Mol. Biol., vol. 161, No. 1, pp. 269-288 (Oct. 25, 1982).
Kuo, E. A. et al., “Synthesis, Structure-Activity Relationships, and Pharmacokinetic Properties of Dihydroorotate Dehydrogenase Inhibitors: 2-Cyano-3-cyclopropyl-3-hydroxy-N-[3′-methyl-4′-(trifluoromethyl)phenyl]propenamide and Related Compounds”,J. Med. Chem., vol. 39, No. 23, pp. 4608-4621 (Nov. 8, 1996).
Mahajan, S. et al., Rational Design and Synthesis of a Novel Anti-leukemic Agent Targeting Bruton's Tyrosine Kinase (BTK), LFM-A13 [α-Cyano-β-Hydroxy-62 -Methyl-N-(2,5-Dibromophenyl)Propenamide],J. Biol. Chem., vol. 274, No. 14, pp. 9587-9599 (Apr. 2, 1999).
Mahajan, S. et al., “Src Family Protein Tyrosine Kinases Induce Autoactivation of Bruton's Tyrosine Kinase”,Mol. Cell. Biol., vol. 15, No. 10, pp. 5304-5311 (Oct. 1995).
Mattar, T. et al., “Inhibition of the Epidermal Growth Factor Receptor Tyrosine Kinase Activity by Leflunomide”FEBS Lett., vol. 334, No. 2, pp. 161-164 (Nov. 1993).
Mendelsohn, J. et al., “Antibodies to Growth Factors and Receptors”,Biologic Therapy of Cancer2nd Edition, pp. 607-623 (1995).
Merritt, E. et al., “Raster3D 2.0 A Program for Photorealistic Molecular Graphics”,Acta Cryst, vol. D50, Part 6, pp. 869-873 (Nov. 1, 1994).
Mirmohammadsadegh, A, et al., “Differential Modulation of Pro- and Antiinflammatory Cytokine Receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide(A77 1726), The Physiologically Active Metabolite of the Novel Immunomodulator Leflunomide”, Chemical Abstracts, vol. 129, No. 3, one page (Jul. 20, 1998).
Mohammadi, M. et al., “Structure of the FGF Receptor Tyrosine Kinase Domain Reveals a Novel Autoinhibitory Mechanism”,Cell, vol. 86, pp. 577-587 (Aug. 23, 1996).
Mohammadi, M. et al., “Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors”,Science, vol. 276, No. 5314, pp. 955960 (May 9, 1997).
Moyer, J. D. et al., “Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase”,Cancer Res., vol. 57, No. 21, pp. 4838-4848 (Nov. 1, 1997).
Nakamura, N. et al., “An Epidermal Growth Factor Receptor/Jak2 Tyrosine Kinase Domain Chimera Induces Tyrosine Phosphorylation of Stat5 and Transduces a Growth Signal in Hematopoietic Cells”,J. Biol. Chem., vol. 271, No. 32, pp. 19483-19488 (Aug. 9, 1996) (Abstract Only).
Naria, R. K. et al., “4-(3-40 -Bromo-4′hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: A Novel Quinazoline Derivative with Potent Cytotoxic Activity against Human Glioblastoma Cells”,Clin., Can. Res., vol. 4, No. 6, pp. 1405-1414 (Jun. 1998).
Palmer, B. D. et al., “Tyrosine Kinase Inhibitors. 11. Soluble Analogues of Pyrroto-and Pyrazoloquinazolines as Epidermal Growth Factor Receptor Inhibitors: Synthesis, Biological Evaluation, and Modeling of the Mode of Binding”,J. Med. Chem., vol. 40, pp. 1519-1529 (1997).
Parnham, M. J., “Leflynomide: A Potential New Disease-Modifying AntiRheu

Affiliated with

Also associated with

Rating

Inhibitors of the EGF-receptor tyrosine kinase and methods... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of the EGF-receptor tyrosine kinase and methods..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of the EGF-receptor tyrosine kinase and methods... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3430341